Picture1.jpg
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
July 25, 2023 06:06 ET | Curium
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
Picture1.jpg
Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)
July 21, 2023 03:30 ET | Curium
PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical...
Picture1.jpg
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
May 26, 2023 03:42 ET | Curium
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
Picture1.jpg
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
May 23, 2023 12:57 ET | Curium
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...
Picture1.jpg
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
March 14, 2023 10:46 ET | Curium
To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
Picture1.jpg
Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion and 10-Year Commitment to St. Louis, MO
March 02, 2023 07:44 ET | Curium
Renaissance in nuclear medicine to attract top St. Louis talentNorth America Headquarters to call Westport Plaza home for the next 10 yearsOver 100 new jobs in the next 3 years ST. LOUIS, March 02,...
Picture1.jpg
Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99
December 21, 2022 10:26 ET | Curium
PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20...
Picture1.jpg
Curium’s Customers to Benefit From Mo-99 Production Restart
November 23, 2022 11:50 ET | Curium
PARIS, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the restarting of a production cycle at the HFR reactor in Petten,...
Picture1.jpg
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
November 22, 2022 00:01 ET | Curium
ST. LOUIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that it intends to submit updated labeling to the U.S. Food and Drug Administration...
Nuclear Medicine Outlook: Proven Molybdenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
November 08, 2022 13:05 ET | Curium
Measures in place minimize impact of near-term molybdenum-99 shortageMore than ten years of Mo-99 supply chain resilienceCooperation, investment, and facility upgrades for the benefit of patients ...